Observational study on predicting treatment response in diffuse large B-cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on patients diagnosed with diffuse large B-cell lymphoma (DLBCL) to understand the factors contributing to primary refractory disease, which affects 30-40% of patients. By utilizing machine learning algorithms, the study aims to predict the likelihood of patients becoming refractory to treatment based on their medical records and various risk factors. The goal is to enable early intervention strategies tailored to individual patient needs, potentially improving treatment outcomes. The study will analyze data from patients treated at the Grand Hôpital de Charleroi, leveraging advanced predictive modeling techniques.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients with diffuse large-cell B lymphoma treated in the haematology department at the Grand Hôpital de Charleroi for the first time
* able to understand the information and sign their consent form

Exclusion Criteria:

* under 18 years old

Where it's running

• Grand Hôpital de Charleroi
  Charleroi, Hainaut, Belgium Recruiting

Study contacts

• Principal investigator: Delphine Pranger, MD — Grand Hôpital de Charleroi
• Study coordinator: Marie Detrait, MD, PhD
• Email: marie.detrait@ghdc.be
• Phone: 0031 71 10

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas

  A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.

  Recruiting at 2 sites Phase 1/2 Umoja Biopharma · Irvine, California and 1 other locations · NCT07735533

• Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma

  This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.

  Recruiting at 41 sites Phase 3 Lyell Immunopharma, Inc. · Gilbert, Arizona and 43 other locations · NCT07188558

• Evaluating treatment options for posttransplant lymphoproliferative disorder

  This study is testing a combination of rituximab and chemotherapy for patients with high-risk posttransplant lymphoproliferative disorder to see if it helps them better than just using rituximab alone.

  Recruiting Phase 2 Columbia University · Stanford, California and 1 other locations · NCT06954805

• CAR-T cell therapy for children with relapsed leukemia or lymphoma

  This study is testing a new CAR-T cell therapy to see if it can help children with relapsed leukemia or lymphoma feel better and improve their chances of recovery.

  Recruiting Hong Kong Children's Hospital · Hong Kong · NCT06866873

• Using CD30 CAR-T therapy for treating relapsed lymphoma

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed lymphoma that has the CD30 marker.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shangxi · NCT06850285

• Testing BTM-3566 for patients with relapsed or refractory mature B cell lymphomas

  This study is testing a new drug called BTM-3566 to see if it can help adults with relapsed or hard-to-treat mature B cell lymphomas feel better and improve their condition.

  Recruiting at 2 sites Phase 1 Bantam Pharmaceuticals · Charlotte, North Carolina and 1 other locations · NCT06792734

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.